Biohaven (BHVN) Could Be 73% Undervalued As Regeneron Deal Expands

Biohaven (BHVN) has expanded its oncology collaboration with Regeneron Pharmaceuticals, leading to recent stock momentum despite a longer history of weak returns and losses. Simply Wall St's Discounted Cash Flow (DCF) model estimates BHVN to be 73% undervalued with a fair value of $54.53 against its current trading price of $14.64, based on assumptions of future revenue and cash generation. However, the company faces significant clinical and regulatory hurdles, and its high Price-to-Book ratio of 180.9x compared to an industry average of 2.5x suggests high valuation risk.